Miraculins Inc
Miraculins is a publicly traded, Canadian biotechnology company (TSX-V:MOM), focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs. The Company’s lead technologies are its point-of-care Scout DS® Non-Invasive Diabetes Test and PreVu® Non-Invasive Skin Cholesterol Test, both of which measure disease biomarkers in the skin within minutes without requiring needles, blood draw or fasting.
Scout DS® Diabetes Screening
The Miraculins Scout DS® is the first non-invasive diabetes testing system designed to provide a highly sensitive and convenient method for measuring diabetes related biomarkers in the skin, associated with abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS® test requires no needles or blood draw, no fasting, and takes only 90 seconds. This exciting new technology, which has been CE Marked and is officially registered with various Member States within the European Union, will be on display at the show with free testing available to delegates – sponsored by Master Investor. Please visit Booth # 6, 7 and 8. Miraculins is a publicly traded Canadian biotechnology company (TSX-V:MOM)
PreVu® Non Invasive Skin Cholesterol Test
The Miraculins PreVu® Test is a revolutionary new assessment technology for risk of coronary artery disease (CAD), that non-invasively measures cholesterol levels in a patient’s skin within minutes, painlessly and without the need for fasting. Elevated levels of skin cholesterol have been clinically shown to be associated with an increased risk of CAD. This exciting new technology, which has been CE Marked and is officially registered with various Member States within the European Union, will be on display at the show with free testing available to delegates – sponsored by Master Investor. Please visit Booth # 6, 7 and 8. Miraculins is a publicly traded Canadian biotechnology company (TSX-V:MOM)